FDA GUIDANCE DOCUMENT: Human Gene Therapy for Rare Diseases

This final guidance provides recommendations for the development of human gene therapy (GT) products for rare diseases. Recognizing the unique challenges — small populations, limited natural history data, and urgent unmet needs — FDA outlines ways to apply regulatory flexibility while maintaining high standards for safety, efficacy, and product quality.

• Covers CMC, nonclinical, and clinical development in an integrated manner to address rare disease challenges.

• Intended to be used alongside other FDA GT guidances (e.g., CMC IND content, LTFU after GT administration).

• Encompasses both monogenic and other rare disorders.

• Core Principle

  • Flexibility within a science- and risk-based framework.

  • Adaptation of development plans is permitted when traditional large-scale approaches are not feasible, provided there is strong scientific justification and an acceptable benefit-risk profile.

  Areas of Flexibility

  1. CMC

     • Robust manufacturing controls and characterization still required.

     • Certain validation studies may be completed post-approval only when scientifically justified and risk-mitigated.

     • Early development of comparability protocols encouraged.

  2. Nonclinical

     • May use a single relevant species.

     • Literature and data from similar GT products may be leveraged.

     • Programs must still provide sufficient safety characterization.

  3. Clinical

     • Alternative designs: single-arm trials, external/historical controls, staggered dosing.

     • Surrogate/intermediate endpoints may support accelerated approval provided they are reasonably likely to predict clinical benefit and accompanied by plans for confirmatory trials.

     • Natural history studies strongly encouraged early in development.

  4. Expedited Programs

     • Sponsors encouraged to engage FDA early and seek Fast Track, Breakthrough, RMAT, or Priority Review where applicable. FDA encourages leveraging existing expedited pathways to accelerate rare disease GT programs in parallel with development flexibilities.